(Q41526219)

2 October 2017

1 reference

title

Epidemiology of acquired immunodeficiency syndrome: advancing to an endemic era. (English)

1 reference

2 October 2017

N M Graham

1

1 reference

2 October 2017

language of work or name

English

0 references

publication date

1 April 1997

1 reference

American Journal of Medicine

2 October 2017

published in

1 reference

2 October 2017

volume

102

1 reference

2 October 2017

issue

4A

1 reference

2 October 2017

page(s)

2-8

1 reference

Scope of the AIDS epidemic in the United States

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Reconstruction and future trends of the AIDS epidemic in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Multifactorial nature of human immunodeficiency virus disease: implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Viral dynamics in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Survival from early, intermediate, and late stages of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Routine prenatal screening for HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Characteristics of Persons with Late AIDS Diagnosis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Access to medical care for black and white Americans. A matter of continuing concern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

Effects of zidovudine therapy in minority and other subpopulations with early HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900031-4

10.1016/S0002-9343(97)00031-4

7 January 2021

Identifiers

DOI

1 reference

2 October 2017

1 reference